

**CURRICULUM VITAE**  
**BRET E. B. FRIDAY, MD, PHD**

**BUSINESS ADDRESS:**

The Duluth Clinic, Ltd.<sup>1</sup>  
400 East Third Street  
Duluth, MN 55805

**PRIMARY PRACTICE SITE:**

The Duluth Clinic, Ltd.<sup>1</sup>  
dba Essentia Health Duluth Clinic  
420 East First Street  
Duluth, MN 55805

**PRESENT POSITIONS:**

2011- Member, Essentia Medical Group-Duluth<sup>2</sup>  
2008- Staff Physician, Section of Hematology/Oncology, Essentia Health  
Virginia Clinic, Virginia, MN  
2002- Staff Physician, Section of Hematology/Oncology, Essentia Health  
Duluth Clinic, Duluth, MN

**AFFILIATIONS:**

The Duluth Clinic, Ltd., dba

- Essentia Health Virginia Clinic
- Essentia Health Hibbing Clinic

**MEDICAL STAFF PRIVILEGES:**

St. Mary's Medical Center, dba

- Essentia Health St. Mary's Medical Center

SMDC Medical Center, dba

- Essentia Health Duluth

**PAST POSITIONS:**

2005-2007 Clinical Investigator Training Program, Mayo Clinic, Rochester, MN  
2004-2008 Physician, Emergency Room and Urgent Care Center  
EnhanceMed Professional Services, Rochester, MN  
2003-2008 Physician, Rochester Family Medicine Clinic, Rochester, MN

**CERTIFICATION:**

2008 American Board of Medical Specialties, Medical Oncology  
2005 American Board of Medical Specialties, Internal Medicine

<sup>1</sup> This facility is a wholly owned subsidiary of Essentia Health. See attached "Essentia Health Facilities". The Essentia Institute of Rural Health, a wholly owned corporation of Essentia Health, is assigned oversight of research and education for Essentia Health.

<sup>2</sup> The Essentia Medical Group was formed to provide a common practice environment for all physicians and credentialed providers within Essentia Health.

**BRET E. B. FRIDAY, MD, PHD**

**PAGE 2:**

**LICENSURE:**

Minnesota

Wisconsin

**EDUCATION:**

1995-2002 Emory University School of Medicine, MD, Atlanta, GA  
1995-2002 Emory University Graduate School of Arts and Science, PhD,  
Atlanta, GA  
1989-1993 Boston University, BA in Biology, Boston, MA

**POSTGRADUATE TRAINING:**

2005-2008 Mayo Clinic, Fellowship, Medical Oncology, Rochester, MN  
2005-2008 Mayo Clinic, Fellowship, Clinical Investigator Training Program in  
Oncology, Rochester, MN  
2002-2005 Mayo Clinic, Residency, Internal Medicine, Rochester, MN

**TEACHING EXPERIENCE:**

1. Emory University School of Medicine, Teaching Assistant for Medical Physiology, 1997,  
1999

**ACADEMIC APPOINTMENTS:**

1997-2001 Emory University - Laboratory of Grace K. Pavlath, PhD, Doctoral  
Thesis Work, Atlanta, GA  
1993-1995 University of Pennsylvania - Laboratory of George Gerton, PhD,  
Research Associate, Philadelphia, PA  
1992-1993 Boston University - Laboratory of Edward Loechler, PhD,  
Undergraduate Research for Distinction, Boston, MA  
1992 Worcester Foundation, Laboratory of Harvey Florman, PhD,  
Summer Research Fellow, Worcester, MA

**HONORS/AWARDS:**

2009 NCCTG Junior Faculty Academic Community Partnership Award  
2008 Mayo Clinic, Outstanding Medical Oncology Fellow  
2005-2006 General Mills Foundation Clinician-Investigator  
2002 Emory University School of Medicine, Cum Laude  
1999-2001 ARCS Foundation Award for Graduate Research  
1993 American Cancer Society, Cancer Federation Award for  
Undergraduate Research  
1993 Boston University, Magna Cum Laude

**COMMITTEES/ADMINISTRATIVE RESPONSIBILITIES:**

2008-2011	Essentia Health Cancer Center Research Committee, Duluth, MN
2008-2010	SMDC Research Committee, Duluth, MN
2007-2008	MCCRC Concept Review and Prioritization Committee, Mayo Clinic, Rochester, MN, Member
2006-2008	Medical Oncology Clinical Practice Committee, Mayo Clinic, Rochester, MN, Fellow Representative
2006-2008	Medical Oncology Hospital In-Patient CPC Subcommittee, Mayo Clinic, Rochester, MN, Fellow Representative
2005-2006	Oncology Division Research Committee, Mayo Clinic, Rochester, MN, Fellow Representative
1998-1999	Molecular Therapeutics and Toxicology Graduate Program, Emory University, Atlanta, GA, Student Representative to the Executive Committee

**PUBLICATIONS - JOURNAL ARTICLES:**

1. Noland TD, Friday BB, Maulit MT, and Gerton GL. The sperm acrosomal matrix contains a novel member of the pentaxin family of calcium-dependent binding proteins. *J Biol Chem* 1994 Dec 23. 269(51):32607-32614. 1994/12/23.
2. Foster JA, Friday BB, Maulit MT, Blobel C, Winfrey VP, Olson GE, Kim KS, and Gerton GL. AM67, a secretory component of the guinea pig sperm acrosomal matrix, is related to mouse sperm protein sp56 and the complement component 4-binding proteins. *J Biol Chem* 1997 May 9. 272(19):12714-12722. 1997/05/09.
3. Abbott KL, Friday BB, Thaloor D, Murphy TJ, and Pavlath GK. Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. *Mol Biol Cell* 1998 Oct. 9(10):2905-2916. 1998/10/08.
4. Friday BB, Horsley V, and Pavlath GK. Calcineurin activity is required for the initiation of skeletal muscle differentiation. *J Cell Biol* 2000 May 1. 149(3):657-666. 2000/05/03.
5. Friday BB and Pavlath GK. A calcineurin- and NFAT-dependent pathway regulates Myf5 gene expression in skeletal muscle reserve cells. *J Cell Sci* 2001 Jan. 114(Pt 2):303-310. 2001/01/10.
6. Horsley V, Friday BB, Matteson S, Kegley KM, Gephart J, and Pavlath GK. Regulation of the growth of multinucleated muscle cells by an NFATC2-dependent pathway. *J Cell Biol* 2001 Apr 16. 153(2):329-338. 2001/04/20.
7. Friday BB, Mitchell PO, Kegley KM, and Pavlath GK. Calcineurin initiates skeletal muscle differentiation by activating MEF2 and MyoD. *Differentiation* 2003 Apr. 71(3):217-227. 2003/04/16.
8. Friday BB and Deb A. Images in cardiovascular medicine. Systemic complications of infective endocarditis. *Circulation* 2005 Nov 15. 112(20):e324. 2005/11/16.
9. Friday BB and Adjei AA. K-ras as a target for cancer therapy. *Biochim Biophys Acta* 2005 Nov 25. 1756(2):127-144. 2005/09/06.
10. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, and Adjei AA. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. *Mol Cancer Ther* 2006 Sep. 5(9):2378-2387. 2006/09/21.
11. Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, and Adjei AA. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase

- inhibitor-induced apoptosis through reactive oxygen species generation. *Clin Cancer Res* 2007 Feb 15. 13(4):1140-1148. 2007/02/24.
12. Steensma DP and Friday BB. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy. *Leuk Lymphoma* 2007 Aug. 48(8):1628-1629. 2007/08/19.
  13. Friday BB and Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. *Clin Cancer Res* 2008 Jan 15. 14(2):342-346. 2008/01/29.
  14. Yu C, Friday BB, Yang L, Atadja P, Wigle D, Sarkaria J, and Adjei AA. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. *Neuro Oncol* 2008 Jun. 10(3):309-319. 2008/05/01.
  15. Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, and Adjei AA. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. *Cancer Res* 2008 Aug 1. 68(15):6145-6153. 2008/08/05.
  16. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. *Neuro-oncology*. 2012;14(2):215-21. Epub 2011/11/18. doi: 10.1093/neuonc/nor198. PubMed PMID: 22090453; PubMed Central PMCID: PMC3266383.

**ABSTRACTS PUBLISHED:**

1. Friday BB, Horsley V, Pavlath GK. Calcineurin activity initiates skeletal muscle differentiation. Presented at Molecular Biology of Muscle Development and Disease, Pacific Grove, CA, May 21-26, 2000.
2. Friday BB, Abbott KL, Miller KM, Murphy TJ, Pavlath GK. NF-AT Regulated Transcription in Skeletal Muscle Cells: NF-AT4 Regulates Expression of Myf5 in Myoblasts. Presented at Gordon Research Conference: Myogenesis, Tilton, NH, August 16-20, 1998.
3. Friday BB, Miller KJ, Pavlath GK. NF-AT4 Regulates Myf-5 Gene Expression in Skeletal Muscle Myoblasts (1998). *Molecular Biology of the Cell* 9:74a.
4. Yu C, Friday BB, Atadja P, Adjei AA. The multi-kinase receptor inhibitor AEE-788 interacts synergistically with Histone Deacetylase (HDAC) inhibitors to induce apoptosis in human malignant cells. 97<sup>th</sup> AACR Annual meeting, Washington DC, April 1-5, 2006.
5. Friday BB, Yu C, Smith PD, Adjei AA. A Potential Role for Modulation of a Negative Feedback Loop between Erk and Raf in Mediating Sensitivity to the MEK inhibitor AZD6244 (ARRY-142886) in Human Lung Cancer Cell Lines. 97<sup>th</sup> AACR Annual meeting, Washington DC, April 1-5, 2006.
6. Friday BB, Yu C, L Yang, P Atadja, D Wigle, J Sarkaria, AA Adjei. Histone deacetylase inhibitors synergistically potentiate proteasome inhibitor-induced apoptosis in glioma cells. ASCO Annual Meeting, Chicago, IL, June 1-5, 2007.
7. Yu C, Tang H, Friday BB, Miner J, Chapman M, Repasky E and Adjei AA. Inhibition of MAPK signaling enhances Sorafenib-mediated cytotoxicity in human cancer cells *in vitro* and *in vivo*. 100th AACR Annual Meeting, Denver, CO, Apr 18-22, 2009.
8. Friday BB, Buckner J, Anderson SK, Giannini C, Kugler J, Mazurczak M, Flynn P, Gross H, Pajon E, Jaeckle K, Galanis E. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group study. 15th

**BRET E. B. FRIDAY, MD, PHD**  
**PAGE 5:**

Annual Meeting of the Society for Neuro-Oncology, Montreal, Quebec, Canada, November 18–21, 2010.